Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Imani

Podiatrist, Foot & Ankle Surgery Charleston, WV Doctor of Podiatric Medicine

NPI 1134183643 CMS profile 187149

4813 MacCorkle Ave Se, Charleston, WV 25304

Open in the dashboard

General payments

$5,172

141 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammad Imani of Charleston, WV is reported in the CMS Open Payments database as having received $5,172 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $596 18
2024 General $597 23
2023 General $612 18
2022 General $711 21
2021 General $1,627 24
2020 General $260 10
2019 General $769 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Imani
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Mohammad Imani were reported at $596. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Mohammad Imani Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $769 $389 $118–$1,406 $163
2020 $260 $191 $62–$691 $114
2021 $1,627 $329 $104–$1,341 $132
2022 $711 $419 $125–$1,611 $149
2023 $612 $377 $128–$1,164 $160
2024 $597 $394 $134–$1,168 $164
2025 $596 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $1,521 52 payments
  2. Treace Medical Concepts, Inc. $1,254 10 payments
  3. Smith+Nephew, Inc. $423 23 payments
  4. Extremity Medical $294 1 payment
  5. Horizon Therapeutics plc $283 7 payments
  6. Amgen Inc. $253 11 payments
  7. Genzyme Corporation $207 8 payments
  8. Ethicon US, LLC $141 1 payment
  9. Stryker Corporation $140 2 payments
  10. Pacira Pharmaceuticals Incorporated $115 1 payment
  11. Other $542 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,322 138 payments
  2. Travel and Lodging $851 3 payments
Products named General payments · program years 2019–2025
  1. Lapiplasty System $1,121 9 payments
  2. Puraply $762 22 payments
  3. IO FiX $294 1 payment
  4. KRYSTEXXA Krystexxa $267 6 payments
  5. KRYSTEXXA Inflammation/Rare Disease $253 11 payments
  6. COLLAGENASE SANTYL $231 13 payments
  7. DUPIXENT $207 8 payments
  8. Apligraf $200 15 payments
  9. REGRANEX Pharma Product $158 8 payments
  10. REGRANEX Pharma Products $155 9 payments
  11. Other $2,163 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

562

Median for Podiatry: 160

Drug cost

$15,269

Median for Podiatry: $2,368

Branded share of claims

2.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 12 $4,122
Pentoxifylline Generic 57 $3,557
Gabapentin Generic 144 $3,138
Diclofenac Sodium Generic 110 $1,026
Pregabalin Generic 21 $930
Terbinafine Hcl Generic 93 $705
Ketoconazole Generic 25 $644
Ciclopirox Generic 23 $529
Topiramate Generic 29 $301
Doxycycline Hyclate Generic 20 $174

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$113,422

Of which drugs: $51,840

Medicare patients

212

Average age 74

Services billed

1,401

105 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Diabetes 56%
Ischemic heart disease 46%
Chronic kidney disease 43%
Depression 34%
Heart failure 24%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 42 168 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $171
$171 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record